Showing results (51-60 of 61) with videos related to
Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2014
Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cellsAaron P Rapoport, Nicole A Aqui, Edward A Stadtmauer, et al.Blood|October 30, 2010
Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myelomaAaron P Rapoport, Nicole A Aqui, Edward A Stadtmauer, et al.Nature Communications|July 3, 2025
Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myelomaDjordje Atanackovic, Tim Luetkens, Dina Schneider, et al.Blood Cancer Journal|December 3, 2021
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentageCarlos Fernández de Larrea, Robert Kyle, Laura Rosiñol, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statementMeletios A Dimopoulos, Jens Hillengass, Saad Usmani, et al.Nature Medicine|October 18, 2005
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transferAaron P Rapoport, Edward A Stadtmauer, Nicole Aqui, et al.American Journal of Hematology|March 23, 2021
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myelomaHolger W Auner, Maria Gavriatopoulou, Sosana Delimpasi, et al.The Lancet. Oncology|December 21, 2019
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 studySagar Lonial, Hans C Lee, Ashraf Badros, et al.American Journal of Hematology|June 1, 2021
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic riskShambavi Richard, Ajai Chari, Sosana Delimpasi, et al.British Journal of Haematology|March 16, 2021
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerationsLaura Rosiñol, Meral Beksac, Elena Zamagni, et al.Pageof 7